Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (12): 1183-1186.DOI: 10.3969/j.issn.1673-8640.2022.12.016
Previous Articles Next Articles
Received:2021-07-19
Revised:2022-09-10
Online:2022-12-30
Published:2023-02-02
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.12.016
| 细菌 | 菌株数 | KPC-2 | NDM-1 | KPC-2+NDM-1 | NDM-5 | KPC-3 |
|---|---|---|---|---|---|---|
| 肺炎克雷伯菌 | 72 | 70 | 2 | 0 | 0 | 0 |
| 大肠埃希菌 | 18 | 0 | 13 | 1 | 4 | 0 |
| 阴沟肠杆菌 | 8 | 0 | 8 | 0 | 0 | 0 |
| 黏质沙雷菌 | 2 | 1 | 0 | 0 | 0 | 1 |
| 合计 | 100 | 71 | 23 | 1 | 4 | 1 |
| 细菌 | 菌株数 | KPC-2 | NDM-1 | KPC-2+NDM-1 | NDM-5 | KPC-3 |
|---|---|---|---|---|---|---|
| 肺炎克雷伯菌 | 72 | 70 | 2 | 0 | 0 | 0 |
| 大肠埃希菌 | 18 | 0 | 13 | 1 | 4 | 0 |
| 阴沟肠杆菌 | 8 | 0 | 8 | 0 | 0 | 0 |
| 黏质沙雷菌 | 2 | 1 | 0 | 0 | 0 | 1 |
| 合计 | 100 | 71 | 23 | 1 | 4 | 1 |
| 耐药基因 | 菌株数 | 碳青霉烯酶抑制剂增强试验 | mCIM/eCIM试验 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDTA | PBA | EDTA+PBA | ||||||||||
| 阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | |||||
| KPC-2 | 71 | 0 | 71 | 70 | 1 | 70 | 1 | 2 | 69 | |||
| NDM-1 | 23 | 23 | 0 | 0 | 23 | 23 | 0 | 23 | 0 | |||
| KPC-2+NDM-1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | |||
| NDM-5 | 4 | 4 | 0 | 0 | 4 | 4 | 0 | 3 | 1 | |||
| KPC-3 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | |||
| 耐药基因 | 菌株数 | 碳青霉烯酶抑制剂增强试验 | mCIM/eCIM试验 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDTA | PBA | EDTA+PBA | ||||||||||
| 阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | |||||
| KPC-2 | 71 | 0 | 71 | 70 | 1 | 70 | 1 | 2 | 69 | |||
| NDM-1 | 23 | 23 | 0 | 0 | 23 | 23 | 0 | 23 | 0 | |||
| KPC-2+NDM-1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | |||
| NDM-5 | 4 | 4 | 0 | 0 | 4 | 4 | 0 | 3 | 1 | |||
| KPC-3 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | |||
| 项目 | 菌株数 | 碳青霉烯酶抑制剂增强实验 | mCIM/eCIM实验 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 敏感性/ % | 特异性/ % | Kappa值 | 阳性预测值/% | 阴性预测值/% | 敏感性/ % | 特异性/ % | Kappa值 | 阳性预测值/% | 阴性预测值/% | |||
| KPC | 72 | 100 | 100 | 0.984 | 100 | 98.30 | 97.22 | 100 | 0.969 | 100 | 96.67 | |
| NDM | 27 | 100 | 100 | 1.000 | 100 | 99.04 | 96.30 | 100 | 0.976 | 100 | 99.04 | |
| KPC+NDM | 1 | 100 | 98.48 | 0.560 | 60.00 | 100 | ① | ① | ① | ① | ① | |
| 阴性 | 30 | 100 | 98.42 | 0.840 | 75.00 | 100 | 100 | 96.28 | 0.700 | 56.25 | 100 | |
| 项目 | 菌株数 | 碳青霉烯酶抑制剂增强实验 | mCIM/eCIM实验 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 敏感性/ % | 特异性/ % | Kappa值 | 阳性预测值/% | 阴性预测值/% | 敏感性/ % | 特异性/ % | Kappa值 | 阳性预测值/% | 阴性预测值/% | |||
| KPC | 72 | 100 | 100 | 0.984 | 100 | 98.30 | 97.22 | 100 | 0.969 | 100 | 96.67 | |
| NDM | 27 | 100 | 100 | 1.000 | 100 | 99.04 | 96.30 | 100 | 0.976 | 100 | 99.04 | |
| KPC+NDM | 1 | 100 | 98.48 | 0.560 | 60.00 | 100 | ① | ① | ① | ① | ① | |
| 阴性 | 30 | 100 | 98.42 | 0.840 | 75.00 | 100 | 100 | 96.28 | 0.700 | 56.25 | 100 | |
| 1 |
SMIBERT O, SATLIN M J, NELLORE A, et al. Carbapenem-resistant Enterobacteriaceae in solid organ transplantation:management principles[J]. Curr Infect Dis Rep, 2019, 21(7):26.
DOI URL |
| 2 | 全国细菌耐药监测网. 全国细菌耐药监测网2014—2019年耐碳青霉烯类肺炎克雷伯菌流行病学变迁[J]. 中国感染控制杂志, 2021, 20(2):175-179. |
| 3 |
TZOUVELEKIS L S, MARKOGIANNAKIS A, PSICHOGIOU M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:an evolving crisis of global dimensions[J]. Clin Microbiol Rev, 2012, 25(4):682-707.
DOI URL |
| 4 |
ZHANG R, LIU L, ZHOU H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae(CRE)strains in China[J]. EBioMedicine, 2017, 19:98-106.
DOI URL |
| 5 |
喻华, 徐雪松, 李敏, 等. 肠杆菌目细菌碳青霉烯酶的实验室检测和临床报告规范专家共识[J]. 中国感染与化疗杂志, 2020, 20(6):671-680.
DOI |
| 6 | Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S28,CLSI, 2020. |
| 7 | 中国医疗保健国际交流促进会临床微生物与感染分会, 中华医学会检验医学分会临床微生物学组,中华医学会微生物学与免疫学分会临床微生物学组. 多黏菌素类与替加环素及头孢他啶/阿维巴坦药敏方法和报告专家共识[J]. 中华检验医学杂志, 2020, 43(10):964-972. |
| 8 | 张凡, 李耘, 甘露, 等. 北京市2016—2017年耐碳青霉烯类肺炎克雷伯菌分子流行病学和遗传特征调查[J]. 中国抗生素杂志, 2020, 45(6):610-620. |
| 9 | WILSON G M, FITZPATRICK M, WALDING K, et al. Meta-analysis of clinical outcomes using ceftazidime/avibactam,ceftolozane/tazobactam,and meropenem/vaborbactam for the treatment of multidrug-resistant gram-negative infections[J]. Open Forum Infect Dis, 2021, 8(2):ofaa 651. |
| 10 | TOOKE C L, HINCHLIFFE P, LANG P A, et al. Molecular basis of class A β-lactamase inhibition by relebactam[J]. Antimicrob Agents Chemother, 2019, 63(10):e00564-19. |
| 11 |
ZHANG W, GUO Y, YANG Y, et al. Study of in vitro synergistic bactericidal activity of dual β-lactam antibiotics against KPC-2-producing Klebsiella pneumoniae[J]. Microb Drug Resist, 2020, 26(3):204-210.
DOI URL |
| 12 |
DORTET L, BRÉCHARD L, POIREL L, et al. Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test[J]. J Med Microbiol, 2014, 63(Pt 5):772-776.
DOI URL |
| 13 |
OVIAÑO M, SPARBIER K, BARBA M J, et al. Universal protocol for the rapid automated detection of carbapenem-resistant Gram-negative bacilli directly from blood cultures by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry(MALDI-TOF/MS)[J]. Int J Antimicrob Agents, 2016, 48(6):655-660.
DOI URL |
| 14 |
DOI Y, POTOSKI B A, ADAMS-HADUCH J M, et al. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound[J]. J Clin Microbiol, 2008, 46(12):4083-4086.
DOI URL |
| 15 |
TSAKRIS A, POULOU A, POURNARAS S, et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates[J]. J Antimicrob Chemother, 2010, 65(8):1664-1671.
DOI PMID |
| 16 | 乔甫, 程棣妍, 司徒永康. 防控产碳青霉烯酶的肠杆菌科细菌新观点[J]. 华西医学, 2019, 34(3):233-242. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
